Enhancement drugs: Are there limits to what we should enhance and why?

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Hesse, Morten ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIDIOL; CANNABIS; DISSOLVED OXYGEN; TETRAHYDROCANNABINOL;

ACCIDENT PREVENTION; ALCOHOL CONSUMPTION; CANNABIS ADDICTION; HEALTH HAZARD; LAW; LIVER INJURY; NOTE; PRIMARY PREVENTION; PSYCHOSIS; PUBLIC HEALTH; RISK REDUCTION; SUBSTANCE ABUSE; ADDICTION; ARTICLE; DRINKING BEHAVIOR; HUMAN;

ALCOHOL DRINKING; CANNABIS; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 77955119236     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-50     Document Type: Note

References (18)

1. Sutton DF. Ancient Comedy. 1993, New York: Twayne Publishers.
2. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Nat Acad Sci USA 1993, 90:5391-5393. 10.1073/pnas.90.12.5391, 46725, 8390660.
3. Eloi-Stiven ML, Channaveeraiah N, Christos PJ, Finkel M, Reddy R. Does marijuana use play a role in the recreational use of sildenafil?. J Family Practice 2007, 56:E1-E4.
4. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 2009, 104:1966-1978. 10.1111/j.1360-0443.2009.02734.x, 19922565.
5. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008, 456:702-705. 10.1038/456702a, 19060880.
6. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nature Rev Genetics 2005, 6:521-532.
7. Soderstrom CA, Cole FJ, Porter JM. Injury in America: the role of alcohol and other drugs--an EAST Position paper prepared by the Injury Control and Violence Prevention Committee. J Trauma Injury, Infection, Crit Care 2001, 50:1-12.
8. Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV. Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol 2010, 24:147-153. 10.1177/0269881109106915, 19939875.
9. Rehm J, Taylor B, Room R. Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev 2006, 25:503-513. 10.1080/09595230600944453, 17132570.
10. Baek IH, Lee BY, Kwon KI. Influence of dissolved oxygen concentration on the pharmacokinetics of alcohol in humans. Alcoholism. Clin Expl Res 2010, 34:834-839.
11. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391. 10.1016/S0140-6736(09)61037-0, 19837255.
12. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004, 99:1333-1341. 10.1111/j.1360-0443.2004.00806.x, 15369572.
13. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004, 99:425-430. 10.1111/j.1360-0443.2004.00683.x, 15049742.
14. Lader M. Addiction and the pharmacology of cannabis: implications for medicine and the law. Med Sci Law 2009, 49:1-17. 10.1258/rsmmsl.49.1.1, 19306615.
15. Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008, 192:306-307. 10.1192/bjp.bp.107.046649, 18378995.
16. Ross SA, Mehmedic Z, Murphy TP, Elsohly MA. GC-MS analysis of the total delta9-THC content of both drug- and fiber-type cannabis seeds. J Analyt Toxicol 2000, 24:715-717.
17. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009, 195:488-491. 10.1192/bjp.bp.109.064220, 19949195.
18. Hall W, Fischer B. Harm reduction policies for cannabis. Harm Reduction: Evidence, Impacts and Challenges 2010, Lisbon: EMCDDA [EMCDDA Monographs], Rhodes T, Hedrich D.